Small-molecule WNK inhibition regulates cardiovascular and renal function

Area of Science:

• Biochemistry
• Pharmacology
• Physiology

Background:

• With-No-Lysine (K) (WNK) kinases are crucial for regulating blood pressure and maintaining body fluid and electrolyte balance.
• Dysregulation of WNK kinase pathways is implicated in various physiological and pathophysiological conditions.

Purpose of the Study:

• To introduce WNK463, the first orally bioavailable inhibitor targeting the pan-WNK-kinase family.
• To investigate the efficacy of WNK463 in modulating blood pressure and fluid homeostasis in preclinical models.

Main Methods:

• Development of a novel pan-WNK-kinase inhibitor, WNK463, designed for high affinity and selectivity.
• Administration of WNK463 to rodent models exhibiting hypertension.
• Assessment of WNK463's impact on blood pressure, body fluid, and electrolyte levels.

Main Results:

• WNK463 demonstrated oral bioavailability.
• The inhibitor effectively modulated blood pressure in rodent models of hypertension.
• WNK463 influenced body fluid and electrolyte homeostasis, aligning with WNK kinase physiology.

Conclusions:

• WNK463 represents a significant advancement as the first orally bioavailable pan-WNK-kinase inhibitor.
• The findings support the therapeutic potential of WNK463 for managing hypertension and related homeostatic disorders.
• Targeting WNK kinases offers a promising strategy for addressing complex physiological regulation.